Ginsenoside Rd for acute ischemic stroke: translating from bench to bedside

References

• Roger VL, Go AS, Lloyd-Jones DM et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation 125(1), e2–e220 (2012).
   PubMed Web of Science ®Google Scholar
• Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 8(4), 355–369 (2009).
   PubMed Web of Science ®Google Scholar
• Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 55(3), 363–389 (2008).
   PubMed Web of Science ®Google Scholar
• Fisher M. New approaches to neuroprotective drug development. Stroke 42(1 Suppl.), S24–S27 (2011).
   PubMed Web of Science ®Google Scholar
• Ginsberg MD. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke 40(3 Suppl.), S111–S114 (2009).
   PubMed Web of Science ®Google Scholar
• O’Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann. Neurol. 59(3), 467–477 (2006).
   PubMed Web of Science ®Google Scholar
• Tymianski M. Can molecular and cellular neuroprotection be translated into therapies for patients?: Yes, but not the way we tried it before. Stroke 41(10 Suppl.), S87–S90 (2010).
   PubMed Web of Science ®Google Scholar
• Philip M, Benatar M, Fisher M, Savitz SI. Methodological quality of animal studies of neuroprotective agents currently in Phase II/III acute ischemic stroke trials. Stroke 40(2), 577–581 (2009).
   PubMed Web of Science ®Google Scholar
• Ginsberg MD. Life after cerovive: a personal perspective on ischemic neuroprotection in the post-NXY-059 era. Stroke 38(6), 1967–1972 (2007).
   PubMed Web of Science ®Google Scholar
• Broussalis E, Trinka E, Killer M, Harrer A, McCoy M, Kraus J. Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies. Drug Discov. Today 17(13–14), 671–684 (2012).
   PubMed Web of Science ®Google Scholar
• Christensen LP. Ginsenosides chemistry, biosynthesis, analysis, and potential health effects. Adv. Food Nutr. Res. 55, 1–99 (2009).
   PubMedGoogle Scholar
• Jia L, Zhao Y. Current evaluation of the millennium phytomedicine – ginseng (I): etymology, pharmacognosy, phytochemistry, market and regulations. Curr. Med. Chem. 16(19), 2475–2484 (2009).
   PubMed Web of Science ®Google Scholar
• Qi LW, Wang CZ, Yuan CS. Isolation and analysis of ginseng: advances and challenges. Nat. Prod. Rep. 28(3), 467–495 (2011).
   PubMed Web of Science ®Google Scholar
• Ma YC, Zhu J, Luo L. A comparative evaluation of ginsenosides in commercial ginseng products and tissue culture samples using HPLC. J. Herb. Species Med. Plants 3(4), 41–50 (1996).
   Google Scholar
• Liu D, Zeng X. A procedure to rapidly isolate ginsenoside Rd from Panax notoginseng. J. Chin. Med. Mater. 29(3), 247–249 (2006).
   Google Scholar
• Yang Z, Chen A, Sun H, Ye Y, Fang W. Ginsenoside Rd elicits Th1 and Th2 immune responses to ovalbumin in mice. Vaccine 25(1), 161–169 (2007).
   PubMedGoogle Scholar
• Bae EA, Choo MK, Park EK, Park SY, Shin HY, Kim DH. Metabolism of ginsenoside R(c) by human intestinal bacteria and its related antiallergic activity. Biol. Pharm. Bull. 25(6), 743–747 (2002).
   PubMed Web of Science ®Google Scholar
• Nah SY, Kim DH, Rhim H. Ginsenosides: are any of them candidates for drugs acting on the central nervous system? CNS Drug Rev. 13(4), 381–404 (2007).
   PubMedGoogle Scholar
• Jung IH, Lee JH, Hyun YJ, Kim DH. Metabolism of ginsenoside Rb1 by human intestinal microflora and cloning of its metabolizing β-d-glucosidase from Bifidobacterium longum H-1. Biol. Pharm. Bull. 35(4), 573–581 (2012).
   PubMed Web of Science ®Google Scholar
• Li J, Xie ZZ, Tang YB, Zhou JG, Guan YY. Ginsenoside-Rd, a purified component from Panax notoginseng saponins, prevents atherosclerosis in apoE knockout mice. Eur. J. Pharmacol. 652(1–3), 104–110 (2011).
   PubMed Web of Science ®Google Scholar
• Cai BX, Li XY, Chen JH et al. Ginsenoside-Rd, a new voltage-independent Ca2+ entry blocker, reverses basilar hypertrophic remodeling in stroke-prone renovascular hypertensive rats. Eur. J. Pharmacol. 606(1–3), 142–149 (2009).
   PubMed Web of Science ®Google Scholar
• Yang ZG, Sun HX, Ye YP. Ginsenoside Rd from Panax notoginseng is cytotoxic towards HeLa cancer cells and induces apoptosis. Chem. Biodivers. 3(2), 187–197 (2006).
   PubMed Web of Science ®Google Scholar
• Yokozawa T, Satoh A, Cho EJ. Ginsenoside-Rd attenuates oxidative damage related to aging in senescence-accelerated mice. J. Pharm. Pharmacol. 56(1), 107–113 (2004).
   PubMed Web of Science ®Google Scholar
• Guan YY, Zhou JG, Zhang Z et al. Ginsenoside-Rd from Panax notoginseng blocks Ca2+ influx through receptor- and store-operated Ca2+ channels in vascular smooth muscle cells. Eur. J. Pharmacol. 548(1–3), 129–136 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang C, Ye R, Han J et al. The effect of ginsenoside Rd on the intracellular free calcium after excitotoxic injury in cultured cortical neurons. Chin. J. Neuroanat. 26(2), 112–118 (2010).
   Google Scholar
• Zhang C, Du F, Shi M et al. Ginsenoside Rd protects neurons against glutamate-induced excitotoxicity by inhibiting Ca(2+) influx. Cell. Mol. Neurobiol. 32(1), 121–128 (2012).
   PubMedGoogle Scholar
• Ye R, Han J, Kong X et al. Protective effects of ginsenoside Rd on PC12 cells against hydrogen peroxide. Biol. Pharm. Bull. 31(10), 1923–1927 (2008).
   PubMed Web of Science ®Google Scholar
• Ye R, Li N, Han J et al. Neuroprotective effects of ginsenoside Rd against oxygen-glucose deprivation in cultured hippocampal neurons. Neurosci. Res. 64(3), 306–310 (2009).
   PubMed Web of Science ®Google Scholar
• Yang L, Deng Y, Xu S, Zeng X. In vivo pharmacokinetic and metabolism studies of ginsenoside Rd. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 854(1–2), 77–84 (2007).
   PubMed Web of Science ®Google Scholar
• Yang L, Xu SJ, Zeng X et al. [Determination of ginsenoside Rd and its metabolites in rat urine by LC-MS]. Yao Xue Xue Bao 41(8), 742–746 (2006).
   PubMedGoogle Scholar
• Sun D, Wang B, Shi M et al. Pharmacokinetic, tissue distribution and excretion of ginsenoside-Rd in rodents. Phytomedicine 19(3–4), 369–373 (2012).
   PubMedGoogle Scholar
• Ye R, Kong X, Yang Q et al. Ginsenoside Rd in experimental stroke: superior neuroprotective efficacy with a wide therapeutic window. Neurotherapeutics 8(3), 515–525 (2011).
   PubMed Web of Science ®Google Scholar
• Wang W, Wang GJ, Xie HT et al. Determination of ginsenoside Rd in dog plasma by liquid chromatography–mass spectrometry after solid-phase extraction and its application in dog pharmacokinetics studies. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852(1–2), 8–14 (2007).
   PubMedGoogle Scholar
• Deng YH, Feng Y, Zeng X et al. [Determination of ginsenoside rd in human plasma by LC/MS/MS]. Zhong Yao Cai 29(9), 928–931 (2006).
   PubMedGoogle Scholar
• Zeng X, Deng Y, Feng Y et al. Pharmacokinetics and safety of ginsenoside Rd following a single or multiple intravenous dose in healthy Chinese volunteers. J. Clin. Pharmacol. 50(3), 285–292 (2010).
   PubMedGoogle Scholar
• Zhang C, Du F, Shi M et al. Ginsenoside Rd protects neurons against glutamate-induced excitotoxicity by inhibiting Ca(2+) influx. Cell. Mol. Neurobiol. 32(1), 121–128 (2012).
   PubMedGoogle Scholar
• Li XY, Liang J, Tang YB, Zhou JG, Guan YY. Ginsenoside Rd prevents glutamate-induced apoptosis in rat cortical neurons. Clin. Exp. Pharmacol. Physiol. 37(2), 199–204 (2010).
   PubMed Web of Science ®Google Scholar
• Lu Y, Peng N, Lu ZH, Sang HF, Yang QZ, Xiong LZ. Neuroprotective effect of ginsenoside Rd predose on brain in rats. Chin. J. Neurosurg. Dis. Res. 8(6), 496–499 (2009).
   Google Scholar
• Yuan LB, Dong HL, Zhang HP, Qu Y, Xiong LZ. Neuroprotective effect of ginsenoside Rd and its combined drug treatment. Chin. J. Neurosurg. Dis. Res. 9(3), 254–257 (2010).
   Google Scholar
• Du XH, Yang JS, Shi XQ, Yan JQ. Effect of ginsenoside Rd pretreatment on the expressions of NR2B receptor and endonuclease G after focal cerebral ischemia–reperfusion in rats. Int. J. Cerebrovasc. Dis. 16(8), 571–575 (2008).
   Google Scholar
• Ye R, Kong X, Yang Q, Zhang Y, Han J, Zhao G. Ginsenoside Rd attenuates redox imbalance and improves stroke outcome after focal cerebral ischemia in aged mice. Neuropharmacology 61(4), 815–824 (2011).
   PubMed Web of Science ®Google Scholar
• Ye R, Yang Q, Kong X et al. Ginsenoside Rd attenuates early oxidative damage and sequential inflammatory response after transient focal ischemia in rats. Neurochem. Int. 58(3), 391–398 (2011).
   PubMed Web of Science ®Google Scholar
• Ye R, Zhang X, Kong X et al. Ginsenoside Rd attenuates mitochondrial dysfunction and sequential apoptosis after transient focal ischemia. Neuroscience 178, 169–180 (2011).
   PubMed Web of Science ®Google Scholar
• Li N, Kong X, Ye R, Yang Q, Han J, Xiong L. Age-related differences in experimental stroke: possible involvement of mitochondrial dysfunction and oxidative damage. Rejuvenation Res. 14(3), 261–273 (2011).
   PubMedGoogle Scholar
• Lipton P. Ischemic cell death in brain neurons. Physiol. Rev. 79(4), 1431–1568 (1999).
   PubMed Web of Science ®Google Scholar
• Guan YY, He H, Chen JX. [Effect of the total saponins of Panax notogiseng on contraction of rabbit aortic strips]. Zhongguo Yao Li Xue Bao 6(4), 267–269 (1985).
   PubMedGoogle Scholar
• Guan YY, Kwan CY, He H, Sun JJ, Daniel EE. Effects of Panax notoginseng saponins on receptor-operated Ca2+ channels in vascular smooth muscle. Zhongguo Yao Li Xue Bao 15(5), 392–398 (1994).
   PubMedGoogle Scholar
• Rhim H, Kim H, Lee DY, Oh TH, Nah SY. Ginseng and ginsenoside Rg3, a newly identified active ingredient of ginseng, modulate Ca2+ channel currents in rat sensory neurons. Eur. J. Pharmacol. 436(3), 151–158 (2002).
   PubMed Web of Science ®Google Scholar
• Nah SY, Park HJ, McCleskey EW. A trace component of ginseng that inhibits Ca2+ channels through a pertussis toxin-sensitive G protein. Proc. Natl Acad. Sci. USA 92(19), 8739–8743 (1995).
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee JH, Goo YS, Nah SY. Effects of ginsenosides on Ca2+ channels and membrane capacitance in rat adrenal chromaffin cells. Brain Res. Bull. 46(3), 245–251 (1998).
   PubMed Web of Science ®Google Scholar
• Lee JH, Jeong SM, Kim JH et al. Effects of ginsenosides and their metabolites on voltage-dependent Ca(2+) channel subtypes. Mol. Cells 21(1), 52–62 (2006).
   PubMed Web of Science ®Google Scholar
• Liu ZQ, Luo XY, Liu GZ, Chen YP, Wang ZC, Sun YX. In vitro study of the relationship between the structure of ginsenoside and its antioxidative or prooxidative activity in free radical induced hemolysis of human erythrocytes. J. Agric. Food Chem. 51(9), 2555–2558 (2003).
   PubMed Web of Science ®Google Scholar
• Yokozawa T, Owada S. Effect of ginsenoside-Rd in cephaloridine-induced renal disorder. Nephron 81(2), 200–207 (1999).
   PubMed Web of Science ®Google Scholar
• Yokozawa T, Liu ZW, Dong E. A study of ginsenoside-Rd in a renal ischemia–reperfusion model. Nephron 78(2), 201–206 (1998).
   PubMed Web of Science ®Google Scholar
• López MV, Cuadrado MP, Ruiz-Poveda OM, Del Fresno AM, Accame ME. Neuroprotective effect of individual ginsenosides on astrocytes primary culture. Biochim. Biophys. Acta 1770(9), 1308–1316 (2007).
   PubMed Web of Science ®Google Scholar
• Jeong HG, Pokharel YR, Han EH, Kang KW. Induction of cyclooxygenase-2 by ginsenoside Rd via activation of CCAAT-enhancer binding proteins and cyclic AMP response binding protein. Biochem. Biophys. Res. Commun. 359(1), 51–56 (2007).
   PubMedGoogle Scholar
• Choi SS, Lee JK, Han EJ et al. Effect of ginsenoside Rd on nitric oxide system induced by lipopolysaccharide plus TNF-α in C6 rat glioma cells. Arch. Pharm. Res. 26(5), 375–382 (2003).
   PubMedGoogle Scholar
• Wu CF, Bi XL, Yang JY et al. Differential effects of ginsenosides on NO and TNF-α production by LPS-activated N9 microglia. Int. Immunopharmacol. 7(3), 313–320 (2007).
   PubMed Web of Science ®Google Scholar
• Lin WM, Zhang YM, Moldzio R, Rausch WD. Ginsenoside Rd attenuates neuroinflammation of dopaminergic cells in culture. J. Neural Transm. Suppl. 72, 105–112 (2007).
   Google Scholar
• Yang XL, Guo TK, Wang YH et al. Ginsenoside Rd attenuates the inflammatory response via modulating p38 and JNK signaling pathways in rats with TNBS-induced relapsing colitis. Int. Immunopharmacol. 12(2), 408–414 (2012).
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang Y, Wang Z et al. Inhibitory effect of ginsenoside-Rd on carrageenan-induced inflammation in rats. Can. J. Physiol. Pharmacol. 90(2), 229–236 (2012).
   PubMedGoogle Scholar
• Leung KW, Wong AS. Pharmacology of ginsenosides: a literature review. Chin. Med. 5, 20 (2010).
   PubMedGoogle Scholar
• Leung KW, Leung FP, Mak NK, Tombran-Tink J, Huang Y, Wong RN. Protopanaxadiol and protopanaxatriol bind to glucocorticoid and oestrogen receptors in endothelial cells. Br. J. Pharmacol. 156(4), 626–637 (2009).
   PubMedGoogle Scholar
• Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat. Med. 8(9), 963–970 (2002).
   PubMed Web of Science ®Google Scholar
• Sun Y, Jin K, Childs JT, Xie L, Mao XO, Greenberg DA. Neuronal nitric oxide synthase and ischemia-induced neurogenesis. J. Cereb. Blood Flow Metab. 25(4), 485–492 (2005).
   PubMed Web of Science ®Google Scholar
• Lin T, Liu Y, Shi M et al. Promotive effect of ginsenoside Rd on proliferation of neural stem cells in vivo and in vitro. J. Ethnopharmacol. 142(3), 754–761 (2012).
   PubMedGoogle Scholar
• Wang B, Feng G, Tang C et al. Ginsenoside Rd maintains adult neural stem cell proliferation during lead-impaired neurogenesis. Neurol. Sci. doi:10.1016/j.expneurol.2012.09.012 (2012) (Epub ahead of print).
   Google Scholar
• Liu J, Lin T, Yan X et al. Effects of infrasound on cell proliferation in the dentate gyrus of adult rats. Neuroreport 21(8), 585–589 (2010).
   PubMedGoogle Scholar
• Liu J, Yan X, Li L et al. Ginsennoside rd attenuates cognitive dysfunction in a rat model of Alzheimer’s disease. Neurochem. Res. 37(12), 2738–2747 (2012).
   PubMedGoogle Scholar
• Li L, Liu Z, Liu J et al. Ginsenoside Rd attenuates β-amyloid-induced τ phosphorylation by altering the functional balance of glycogen synthase kinase 3β and protein phosphatase 2A. Neurobiol. Dis. doi:10.1016/j.nbd.2013.01.002 (2013) (Epub ahead of print).
   Google Scholar
• Liu X, Xia J, Wang L et al. Efficacy and safety of ginsenoside-Rd for acute ischaemic stroke: a randomized, double-blind, placebo-controlled, Phase II multicenter trial. Eur. J. Neurol. 16(5), 569–575 (2009).
   PubMed Web of Science ®Google Scholar
• Liu X, Wang L, Wen A et al. Ginsenoside-Rd improves outcome of acute ischaemic stroke – a randomized, double-blind, placebo-controlled, multicenter trial. Eur. J. Neurol. 19(6), 855–863 (2012).
   PubMed Web of Science ®Google Scholar
• Chavez JC, Hurko O, Barone FC, Feuerstein GZ. Pharmacologic interventions for stroke: looking beyond the thrombolysis time window into the penumbra with biomarkers, not a stopwatch. Stroke 40(10), e558–e563 (2009).
   PubMed Web of Science ®Google Scholar
• Ye R, Yang Q, Kong X et al. Sevoflurane preconditioning improves mitochondrial function and long-term neurologic sequelae after transient cerebral ischemia: role of mitochondrial permeability transition. Crit. Care Med. 40(9), 2685–2693 (2012).
   PubMed Web of Science ®Google Scholar
• Feuerstein GZ, Chavez J. Translational medicine for stroke drug discovery: the pharmaceutical industry perspective. Stroke 40(3 Suppl.), S121–S125 (2009).
   PubMed Web of Science ®Google Scholar
• Xue D, Slivka A, Buchan AM. Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats. Stroke 23(6), 894–899 (1992).
   PubMed Web of Science ®Google Scholar
• Lou M, Eschenfelder CC, Herdegen T, Brecht S, Deuschl G. Therapeutic window for use of hyperbaric oxygenation in focal transient ischemia in rats. Stroke 35(2), 578–583 (2004).
   PubMed Web of Science ®Google Scholar
• Minnerup J, Schäbitz WR. Multifunctional actions of approved and candidate stroke drugs. Neurotherapeutics 6(1), 43–52 (2009).
   PubMed Web of Science ®Google Scholar
• Kaste M. Is there a future for neuroprotective agents in acute ischaemic stroke? Eur. J. Neurol. 19(6), 797–798 (2012).
   PubMedGoogle Scholar
• Lipton SA. Pathologically activated therapeutics for neuroprotection. Nat. Rev. Neurosci. 8(10), 803–808 (2007).
   PubMed Web of Science ®Google Scholar
• Kaste M, Fogelholm R, Erilä T et al. A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 25(7), 1348–1353 (1994).
   PubMed Web of Science ®Google Scholar
• Trust Study Group. Randomised, double-blind, placebo-controlled trial of nimodipine in acute stroke. Lancet 336(8725), 1205–1209 (1990).
   PubMed Web of Science ®Google Scholar
• Shuaib A, Lees KR, Lyden P et al.; SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N. Engl. J. Med. 357(6), 562–571 (2007).
   PubMed Web of Science ®Google Scholar
• Feuerstein GZ, Zaleska MM, Krams M et al. Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J. Cereb. Blood Flow Metab. 28(1), 217–219 (2008).
   PubMed Web of Science ®Google Scholar
• Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp. Neurol. 205(1), 20–25 (2007).
   PubMed Web of Science ®Google Scholar
• STAIR. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30(12), 2752–2758 (1999).
   PubMed Web of Science ®Google Scholar
• Fisher M, Feuerstein G, Howells DW et al.; STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40(6), 2244–2250 (2009).
   PubMed Web of Science ®Google Scholar
• Minnerup J, Wersching H, Diederich K et al. Methodological quality of preclinical stroke studies is not required for publication in high-impact journals. J. Cereb. Blood Flow Metab. 30(9), 1619–1624 (2010).
   PubMedGoogle Scholar
• Amemiya S, Kamiya T, Nito C et al. Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats. Eur. J. Pharmacol. 516(2), 125–130 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang N, Komine-Kobayashi M, Tanaka R, Liu M, Mizuno Y, Urabe T. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 36(10), 2220–2225 (2005).
   PubMed Web of Science ®Google Scholar
• Nishi H, Watanabe T, Sakurai H, Yuki S, Ishibashi A. Effect of MCI-186 on brain edema in rats. Stroke 20(9), 1236–1240 (1989).
   PubMed Web of Science ®Google Scholar
• Kawai H, Nakai H, Suga M, Yuki S, Watanabe T, Saito KI. Effects of a novel free radical scavenger, MCl-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J. Pharmacol. Exp. Ther. 281(2), 921–927 (1997).
   PubMed Web of Science ®Google Scholar
• Mizuno A, Umemura K, Nakashima M. Inhibitory effect of MCI-186, a free radical scavenger, on cerebral ischemia following rat middle cerebral artery occlusion. Gen. Pharmacol. 30(4), 575–578 (1998).
   PubMedGoogle Scholar
• Wu TW, Zeng LH, Wu J, Fung KP. MCI-186: further histochemical and biochemical evidence of neuroprotection. Life Sci. 67(19), 2387–2392 (2000).
   PubMed Web of Science ®Google Scholar
• Takamatsu H, Kondo K, Ikeda Y, Umemura K. Neuroprotective effects depend on the model of focal ischemia following middle cerebral artery occlusion. Eur. J. Pharmacol. 362(2–3), 137–142 (1998).
   PubMedGoogle Scholar
• Shichinohe H, Kuroda S, Yasuda H et al. Neuroprotective effects of the free radical scavenger edaravone (MCI-186) in mice permanent focal brain ischemia. Brain Res. 1029(2), 200–206 (2004).
   PubMed Web of Science ®Google Scholar
• Watanabe T, Yuki S, Egawa M, Nishi H. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J. Pharmacol. Exp. Ther. 268(3), 1597–1604 (1994).
   PubMed Web of Science ®Google Scholar
• Srinivasan K, Sharma SS. Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress. Basic Clin. Pharmacol. Toxicol. doi:10.1111/j.1742-7843.2011.00763.x (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Nakashima M, Niwa M, Iwai T, Uematsu T. Involvement of free radicals in cerebral vascular reperfusion injury evaluated in a transient focal cerebral ischemia model of rat. Free Radic. Biol. Med. 26(5–6), 722–729 (1999).
   PubMed Web of Science ®Google Scholar
• Watanabe T, Tahara M, Todo S. The novel antioxidant edaravone: from bench to bedside. Cardiovasc. Ther. 26(2), 101–114 (2008).
   PubMed Web of Science ®Google Scholar
• Sun HS, Doucette TA, Liu Y et al. Effectiveness of PSD95 inhibitors in permanent and transient focal ischemia in the rat. Stroke 39(9), 2544–2553 (2008).
   PubMed Web of Science ®Google Scholar
• Bråtane BT, Cui H, Cook DJ, Bouley J, Tymianski M, Fisher M. Neuroprotection by freezing ischemic penumbra evolution without cerebral blood flow augmentation with a postsynaptic density-95 protein inhibitor. Stroke 42(11), 3265–3270 (2011).
   PubMed Web of Science ®Google Scholar
• Aarts M, Liu Y, Liu L et al. Treatment of ischemic brain damage by perturbing NMDA receptor–PSD-95 protein interactions. Science 298(5594), 846–850 (2002).
   PubMed Web of Science ®Google Scholar
• Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature 483(7388), 213–217 (2012).
   PubMed Web of Science ®Google Scholar
• Kaste M. Is the door open again for neuroprotection trials in stroke? Lancet Neurol. 11(11), 930–931 (2012).
   PubMedGoogle Scholar
• Hill MD, Martin RH, Palesch YY et al.; ALIAS Investigators; Neurological Emergencies Treatment Trials Network. The Albumin in Acute Stroke Part 1 Trial: an exploratory efficacy analysis. Stroke 42(6), 1621–1625 (2011).
   PubMedGoogle Scholar
• Hacke W, Kaste M, Bluhmki E et al.; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359(13), 1317–1329 (2008).
   PubMed Web of Science ®Google Scholar
• Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc. Dis. 15(3), 222–229 (2003).
   PubMed Web of Science ®Google Scholar
• Dávalos A, Alvarez-Sabín J, Castillo J et al.; International Citicoline Trial on Acute Stroke (ICTUS) trial investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 380(9839), 349–357 (2012).
   PubMed Web of Science ®Google Scholar
• Cook DJ, Tymianski M. Nonhuman primate models of stroke for translational neuroprotection research. Neurotherapeutics 9(2), 371–379 (2012).
   PubMed Web of Science ®Google Scholar
• Dolgin E. To serve and neuroprotect. Nat. Med. 18(7), 1003–1006 (2012).
   PubMedGoogle Scholar
• Sanossian N, Starkman S, Eckstein M et al.; FAST-MAG Trial Investigators. Intercontinental elicitation of informed consent for enrollment in stroke research. Cerebrovasc. Dis. 30(3), 323–324 (2010).
   PubMedGoogle Scholar
• Liu R, Yuan H, Yuan F, Yang SH. Neuroprotection targeting ischemic penumbra and beyond for the treatment of ischemic stroke. Neurol. Res. 34(4), 331–337 (2012).
   PubMed Web of Science ®Google Scholar
• Yu GL, Wei EQ, Zhang SH et al. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice. Pharmacology 73(1), 31–40 (2005).
   PubMedGoogle Scholar
• Takizawa S, Izuhara Y, Kitao Y et al. A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia. Brain Res. 1183, 124–137 (2007).
   PubMed Web of Science ®Google Scholar
• Nakajima H, Kakui N, Ohkuma K, Ishikawa M, Hasegawa T. A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats. J. Pharmacol. Exp. Ther. 312(2), 472–481 (2005).
   PubMedGoogle Scholar
• Satoh S, Toshima Y, Ikegaki I, Iwasaki M, Asano T. Wide therapeutic time window for fasudil neuroprotection against ischemia-induced delayed neuronal death in gerbils. Brain Res. 1128(1), 175–180 (2007).
   PubMedGoogle Scholar